The oral flu vaccine is still at least five years away from market, according to Sean Tucker, chief science officer at VAXART. Tucker told Fox News in an email that research is also ongoing in animals to make the upcoming universal flu vaccine (which targets the “stalk” of the flu hemagglutinin protein) available in pill form.
There just might be a company to beat it by years end:
As part of this Phase 3 study, cell-mediated immunogenicity markers of M-001 will be evaluated in a subset of participants. The recently completed clinical study report (CSR) of a U.S. National Institute of Allergy and Infectious Diseases (NIAID) supported Phase 2 clinical trial of M-001 concluded that, "M-001 induced significant polyfunctional T cell responses."
In addition to the ongoing pivotal, clinical efficacy, Phase 3 trial, equipment installation and manufacturing process scale-up in BiondVax's pilot facility in Jerusalem are in progress. The facility has planned annual capacity of up to between 10 and 20 million doses in bulk.
News 
Market Data 
Discover 
